Brasky and colleagues (1) report that, within the Selenium and Vitamin E Cancer Prevention Trial, plasma phospholipid levels of long-chain omega-3 fatty acids measured in blood samples collected at baseline are positively associated with subsequent risk for low-grade, high-grade, and total prostate cancer (1). They then perform a meta-analysis incorporating previous pertinent prospective case-control studies that appears to sustain this conclusion. In their discussion, the authors indicate that their findings strongly suggest that long-chain omega3s play a causative role in prostate cancer induction and caution that "general recommendations to increase long-chain ω-3 PUFA intake should consider its potential risks" (1) . Subsequent media coverage of this study has created the impression that dietary omega-3 fatty acids may be dangerous.
Whether a positive correlation between plasma omega-3 and prostate cancer risk will be sustained in future research remains to be seen. As the authors note, previous pertinent studies have had variable results. In fact, a meta-analysis published earlier this yearbefore the availability of Brasky et al.'s (1) new data-concluded that plasma omega-3 levels are not associated with risk for total or advanced prostate cancer, aside from an inverse association with docosapentaenoic acid (2) . (A positive association between omega-3 status and risk for advanced prostate cancer emerged only after results from the Physician's Health Study were excluded.) Furthermore, even if subsequent research does confirm a positive correlation between plasma omega-3s and prostate cancer risk, it will not be clear that this association is causative. Arguably, some peculiarity of metabolism might affect the distribution and oxidation of omega-3s while concurrently modulating prostate cancer risk. The notion that long-chain omega-3s play a pathogenic role in prostate cancer induction is not supported by the many studies that have analyzed fish ingestion and prostate cancer risk. In a recent meta-analysis of these studies, Szymanski et al. observed a modest inverse association between fish consumption and prostate cancer risk in case-control studies (odds ratio = 0.85; 95% confidence interval [CI] = 0.72 to 1.00; P = .05), albeit no association was observed in cohort studies; in the four included studies that reported prostate cancer-specific mortality, fish consumption was linked to a strong reduction in this mortality (relative risk = 0.37; 95% CI = 0.18 to 0.74; P = .005) (3). Moreover, epidemiology also suggests that frequent fish consumption improves survival in men who already have prostate cancer (4, 5) . And diets enriched in fish oil, or in the terrestrial omega-3 stearidonic acid (readily converted to eicosapentaenoic acid within the body), have slowed the growth of human prostate cancers in nude mice (6) .
The traditional diets of the Japanese and of Inuits are notable for their exceptionally high omega-3 content; in past decades, the mortality from prostate cancer among these peoples has been very low compared with Western rates (7) .
In light of the physiological role that myocardial omega-3s play in the prevention of arrhythmias and of suggestive evidence that replete omega-3 status may slow age-related cognitive decline, it is inappropriate to suggest that these fatty acids may increase prostate cancer risk while failing to cite the considerable evidence that appears to contradict this position.
